Development of differentiation modulators and targeted agents for treating neuroblastoma

Jin, Zegao; Yang, Lu; Wu, Yizhe; Che, Jinxin; Dong, Xiaowu

doi:10.1016/j.ejmech.2020.112818

Cited by 17 publications

(17 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Effective immunotherapy can improve the survival rate and quality of NB patients by reducing exposure to cytotoxic agents. GD2 , a surface glycolipid, is the most common target of immunotherapy ( Sait and Modak, 2017 ; Jin et al, 2020 ). However, when anti- GD2 monoclonal antibody was integrated into the standard upfront treatment regimen, the 5-year survival rate for NB patients is only about 50%.…”

Section: Current Research Progress On Nbmentioning

confidence: 99%

“…Differentiation therapy, as a new treatment method, has made some progress in the maintenance treatment of high-risk NB patients in recent years. The differentiation therapy involves reactivating the intrinsic differentiation program in cancer cells and forcing them to differentiate into mature, supposedly more benign cells ( Jin et al, 2020 ). Retinoic acid is one of the differentiation modulators in cancer therapy ( Brodeur and Bagatell, 2014 ).…”

Section: Current Research Progress On Nbmentioning

confidence: 99%

See 1 more Smart Citation

Therapy resistance in neuroblastoma: Mechanisms and reversal strategies

Zhou

Wang²,

Li³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Neuroblastoma is one of the most common pediatric solid tumors that threaten the health of children, accounting for about 15% of childhood cancer-related mortality in the United States. Currently, multiple therapies have been developed and applied in clinic to treat neuroblastoma including chemotherapy, radiotherapy, targeted therapy, and immunotherapy. However, the resistance to therapies is inevitable following long-term treatment, leading to treatment failure and cancer relapse. Hence, to understand the mechanisms of therapy resistance and discover reversal strategies have become an urgent task. Recent studies have demonstrated numerous genetic alterations and dysfunctional pathways related to neuroblastoma resistance. These molecular signatures may be potential targets to combat refractory neuroblastoma. A number of novel interventions for neuroblastoma patients have been developed based on these targets. In this review, we focus on the complicated mechanisms of therapy resistance and the potential targets such as ATP-binding cassette transporters, long non-coding RNAs, microRNAs, autophagy, cancer stem cells, and extracellular vesicles. On this basis, we summarized recent studies on the reversal strategies to overcome therapy resistance of neuroblastoma such as targeting ATP-binding cassette transporters, MYCN gene, cancer stem cells, hypoxia, and autophagy. This review aims to provide novel insight in how to improve the therapy efficacy against resistant neuroblastoma, which may shed light on the future directions that would enhance the treatment outcomes and prolong the survival of patients with neuroblastoma.

show abstract

Section: Current Research Progress On Nbmentioning

confidence: 99%

Section: Current Research Progress On Nbmentioning

confidence: 99%

Therapy resistance in neuroblastoma: Mechanisms and reversal strategies

Zhou

Wang²,

Li³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The formation of new synapses and development of neural plasticity are modulated by neurotrophins, such as neural growth factor (NGF) and brain derived neurotrophic factor (BDNF), which act trough membrane receptors, including tyrosine kinase A (TrkA) receptor [ 1 ]. Although promotion of differentiation has been proposed as a potential therapy in the treatment of children suffering from neuroblastoma [ 2 ], a better understanding of the mechanisms that regulate neurite outgrowth and differentiation will provide further evidences to support new clinical trials.…”

Section: Introductionmentioning

confidence: 99%

Neurite outgrowth induced by stimulation of angiotensin II AT2 receptors in SH-SY5Y neuroblastoma cells involves c-Src activation

Blanco¹,

Perez²,

Banchio³

et al. 2023

Heliyon

View full text Add to dashboard Cite

“… 3 These mechanisms provide a theoretical basis for NB differentiation therapy, whereby malignant tumor cells are induced to differentiate into normal or benign cells. 5 However, additional mechanisms are likely to govern spontaneous regression, and exploring these mechanisms may provide new strategies for differentiation therapy.…”

Section: Introductionmentioning

confidence: 99%